Cardiovascular risk assessment in the treatment of nonalcoholic steatohepatitis: a secondary analysis of the MOZART trial

Background: Nonalcoholic steatohepatitis (NASH) is associated with increased cardiovascular risk and mortality. No US Food and Drug Administration (FDA) approved therapies for NASH are available; clinical trials to date have not yet systematically assessed for changes in cardiovascular risk. This st...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Steven C. Lin, Brandon Ang, Carolyn Hernandez, Ricki Bettencourt, Rashmi Jain, Joanie Salotti, Lisa Richards, Yuko Kono, Archana Bhatt, Hamed Aryafar, Grace Y. Lin, Mark A. Valasek, Claude B. Sirlin, Sharon Brouha, Rohit Loomba
Μορφή: Άρθρο
Γλώσσα:English
Έκδοση: SAGE Publishing 2016-03-01
Σειρά:Therapeutic Advances in Gastroenterology
Διαθέσιμο Online:https://doi.org/10.1177/1756283X15621232

Παρόμοια τεκμήρια